The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …

Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …

This ESMO Clinical Practice Guideline provides updated state-of-the-art recommendations
on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a …

Background: The American Thyroid Association (ATA) management guidelines for patients
with thyroid nodules and differentiated thyroid cancer (DTC) are highly influential practice …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Thyroid cancer can be largely classified as well-differentiated, poorly differentiated,
medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and …

A more conservative approach to the clinical management of thyroid nodules and
differentiated thyroid cancer has recently been proposed by the 2015 ATA guidelines. In this …

Abstract Leucine‑rich‑alpha‑2‑glycoprotein 1 (LRG‑1) has been reported to be associated
with multiple malignancies. However, its participation in thyroid carcinoma progression …

Objective: This institutional study sought to retrospectively evaluate disease progression and
survival of patients with differentiated thyroid cancer (DTC) and bone metastases (BM) and …

Background Tyrosine kinase inhibitors (TKIs) have been administered to advanced or radio-
iodine refractory differentiated thyroid carcinoma (RR-DTC) patients for years. We performed …